Safety and efficacy of Tenofovir alafenamide (TAF) in patients with chronic hepatitis B and cirrhosis.
Not Applicable
Recruiting
- Conditions
- Chronic hepatitis B and cirrhosis
- Registration Number
- JPRN-UMIN000034362
- Lead Sponsor
- ippon Medical Chiba Hokusoh Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who has allergy to this drugs. 2.Patients with severe kidney disease. 3.Patients who are taking Tenofovir. 4.Patients who are pregnant or breast-feeding. 5.Patients who are judged ineligible by atending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rates of negativity of hepatitis B surface antigen. The amount of reduction of hepatitis B surface antigen.
- Secondary Outcome Measures
Name Time Method